The pathogenetic role of NLRP3 inflammasome activation in different kidney diseases is further supported by in vitro and in vivo evidence showing that the inhibition of NLRP3 signalling pathways often alleviates kidney injury, making the inflammasome a potential target in the treatment of renal disease [53]. Here, NLRP3 is linked to kidney disorder.